AbbVie Gets FDA Expanded Nod for Rinvoq in Crohn's Disease
By Colin Kellaher
AbbVie on Thursday said the Food and Drug Administration has approved the expanded use of its blockbuster immunology drug Rinvoq for adults with moderately to severely active Crohn's disease.
The North Chicago, Ill., company said the approval covers Rinvoq as a once-daily pill for adults with the chronic inflammatory bowel disorder who have had an inadequate response or intolerance to one or more TNF blockers and marks the seventh FDA nod for the drug across rheumatology, dermatology and gastroenterology.
AbbVie is counting on Rinvoq and its blockbuster psoriasis drug Skyrizi to help make for lost sales for its mega-blockbuster Humira, the highest-grossing drug of all time, which faces new competition from copycats after patent expirations.
AbbVie is targeting combined 2025 risk-adjusted sales for Rinvoq and Skyrizi of more than $17.5 billion and combined peak sales for the two drugs topping $21 billion in 2027.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 18, 2023 13:40 ET (17:40 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
Will Earnings From These 10 AI Stocks Live Up to the Hype?
-
What’s Happening In the Markets This Week
-
What the Next Bitcoin Halving Means for ETF Investors
-
Going Into Earnings, Is Microsoft a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Netflix Stock a Buy, a Sell, or Fairly Valued?
-
ServiceNow Earnings: Strong Quarter With In-Line Guidance and Increasingly Attractive Valuation
-
Ford Earnings: Pro Continues to Impress While EV Costs Are Contained
-
Boeing Earnings: Paying for Mistakes Made Long Ago, Taking Back the Factory Floor
-
Meta Earnings: Stock Now Fairly Valued After Latest Selloff
-
March PCE Inflation Index Forecasts Show Mixed Readings On Price Pressures
-
After Earnings, Is Charles Schwab Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Apple Stock a Buy, a Sell, or Fairly Valued?